PDCD1 and gastric cancer: The results of this trial are consistent with findings from a global cohort of patients with GC/GEJC treated in the JAVELIN Solid Tumor trial [29], and previous phase 1 and 2 studies of anti-PD-1 antibodies [21, 35, 36].